Fremont, CA, United States of America

Albert Gacerez

This inventor holds 1 USPTO granted patent. Top assignee: Chimera Bioengineering, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Albert Gacerez. Retrieved from https://idiyas.com/inventor/albert-gacerez-nv0a48ri

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Albert Gacerez: Innovator in CAR T-cell Therapy

Introduction

Albert Gacerez is a notable inventor based in Fremont, CA. He has made significant contributions to the field of biotechnology, particularly in the development of CAR T-cell therapies. His innovative work focuses on enhancing cancer treatment through advanced cellular engineering.

Latest Patents

Gacerez holds a patent for "Compositions and Methods for Anti-TnMUC1 Gold CAR T-cells." This patent represents a breakthrough in the application of CAR T-cell technology, aimed at improving the efficacy of cancer therapies.

Career Highlights

Currently, Albert Gacerez is employed at Chimera Bioengineering, Inc. His role at the company allows him to work on cutting-edge research and development projects that aim to revolutionize cancer treatment methodologies.

Collaborations

Gacerez collaborates with talented individuals such as Benjamin Wang and Gusti Zeiner. Together, they contribute to the advancement of innovative solutions in the field of biotechnology.

Conclusion

Albert Gacerez is a prominent figure in the realm of CAR T-cell therapy, with a focus on innovative approaches to cancer treatment. His work continues to inspire advancements in biotechnology and therapeutic applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…